Alpha-2a Adrenergic Receptor Modulators and Uses Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel modulators (especially agonists) of the alpha-2A adrenergic receptor (α2AAR) for the treatment of pain. These small-molecule compounds are structurally distinct from existing α2AAR drugs like dexmedetomidine and clonidine. The new compounds were identified using virtual screening and structure-based drug design, leading to the discovery of analgesic molecules with potent activity and a reduced risk of sedation. Some of the newly invented molecules show strong pain-relieving effects in preclinical models of neuropathic, inflammatory, and acute pain, but do not cause the sedation commonly seen with existing α2AAR agonists.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of new non-opioid pain medications for acute or chronic pain management.
• Treatment of neuropathic pain (e.g., pain from nerve injuries, diabetic neuropathy, post-herpetic neuralgia).
• Treatment of post-operative pain, including pediatric and gynecological surgery pain.
• Management of inflammatory pain caused by conditions such as rheumatoid arthritis or osteoarthritis.
• Use as adjunct to opioids, reducing opioid dose requirements and side effects.
• Potential application for pain that is refractory to standard treatments, including opioid-refractory pain and certain types of headaches (e.g., migraine, rebound headache).

BenefitsContent extracted from patent full text and abstract with AI.

• Non-opioid mechanism of action, reducing the risk of addiction or opioid-related side effects.
• Reduced risk of sedation compared to current α2AAR agonists like dexmedetomidine, enabling broader applicability for outpatient or ambulatory pain management.
• Orally bioavailable compounds, improving ease of administration compared to current intravenous-only options.
• Potential to disentangle analgesic effects from sedative effects at the same receptor, allowing safer pain relief.
• Favorable selectivity and safety profile in preclinical testing, with limited off-target effects and low risk of cardiovascular or motor impairment.
• Effective in multiple types of pain (neuropathic, inflammatory, acute, post-surgical) in animal models.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Described herein, inter alia, are 0.2 A adrenergic receptor agonists and uses thereof.